The viral oncogene Np9 acts as a critical molecular switch for co-activating β-catenin, ERK, Akt and Notch1 and promoting the growth of human leukemia stem/progenitor cells

Leukemia

Volumn 27, Issue 7, 2013, Pages 1469-1478

  Huang, W ^b   Chen, T ^a   Meng, Z ^b   Gan, Y ^a   Wang, X ^b   Xu, F ^a   Gu, Y ^a,b   Xu, X ^a   Tang, J ^a   Zhou, H ^a   Zhang, X ^a,a   Gan, X ^c   Van Ness, C ^b   Xu, G ^a   Huang, L ^a   Fang, Y ^a   Wu, J ^a   Zheng, S ^a   Jin, J ^a   Xu, R ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

catenin; Akt; ERK; HERV K; Leukemia stem cell; Np9

Indexed keywords

BETA CATENIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYC PROTEIN; NOTCH1 RECEPTOR; PROTEIN KINASE B; SHORT HAIRPIN RNA;

ANIMAL EXPERIMENT; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER STEM CELL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME ACTIVATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA; MOUSE; NONHUMAN; NP9 GENE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; TRANSMISSION ELECTRON MICROSCOPY; UPREGULATION; VIRUS ONCOGENE; WESTERN BLOTTING;

ANIMALS; BETA CATENIN; CELL LINE, TUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE PRODUCTS, ENV; GENES, ENV; GENES, POL; HEMATOPOIETIC STEM CELLS; HL-60 CELLS; HUMANS; JURKAT CELLS; K562 CELLS; LEUKEMIA, MYELOID; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOPLASTIC STEM CELLS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, NOTCH1;

EID: 84880275710     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.8     Document Type: Article

References (35)

1. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980; 77: 7415-7419.
2. Miyoshi I, Kubonishi I, Yoshimoto S, Akagi T, Ohtsuli Y, Shiraishi Y et al. Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature 1981; 294: 770-771.
3. Lander ES, Linton LM, Birren B, Nubaum C, Zody MC, Baldwin J et al. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
4. Costas J. Characterization of the intragenomic spread of the human endogenous retrovirus family HERV-W. Mol Biol Evol 2002; 19: 526-533.
5. Hughes JF, Coffin JM. Evidence for genomic rearrangements mediated by human endogenous retroviruses during primate evolution. Nat Genet 2001; 29: 487-489.
6. Dewannieux M, Harper F, Richaud A, Letzelter C, Ribet D, Pierron G et al. Identification of an infectious progenitor for the multiple-copy HERV-K human endogenous retroelements. Genome Res 2006; 16: 1548-1556.
7. Tönjes RR, Löwer R, Boller K, Denner J, Hasenmaier B, Kirsch H et al. HERV-K: the biologically most active human endogenous retrovirus family. Acquir Immune Defic Syndr Hum Retrovirol 1996; 13: S261-S267.
8. Kraus B, Boller K, Reuter A, Schnierle BS. Characterization of the human endogenous retrovirus K Gag protein: identification of protease cleavage sites. Retrovirology 2011; 8: 21.
9. Barbulescu M, Turner G, Seaman MI, Deinard AS, Kidd KK, Lenz J. Many human endogenous retrovirus K (HERV-K) proviruses are unique to humans. Curr Biol 1999; 9: 861-868.
10. Hanke K, Kramer P, Seeher S, Beimforde N, Kurth R, Bannert N. Reconstitution of the ancestral glycoprotein of human endogenous retrovirus k and modulation of its functional activity by truncation of the cytoplasmic domain. J Virol 2009; 83: 12790-12800.
11. Boller K, Schönfeld K, Lischer S, Fischer N, Hofmann A, Kurth R et al. Human endogenous retrovirus HERV-K113 is capable of producing intact viral particles. J Gen Virol 2008; 89: 567-572.
12. Lee YN, Bieniasz PD. Reconstitution of an infectious human endogenous retrovirus. PLoS Pathog 2007; 3: e10.
13. Contreras-Galindo R, Almodó var-Camacho S, González- Ramírez S, Lorenzo E, Yamamura Y. Comparative longitudinal studies of HERV-K and HIV-1 RNA titers in HIV-1-infected patients receiving successful versus unsuccessful highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2007; 23: 1083-1086.
14. Depil S, Roche C, Dussart P, Prin L. Expression of a human endogenous retrovirus, HERV-K, in the blood cells of leukemia patients. Leukemia 2002; 16: 254-259.
15. Contreras-Galindo R, Kaplan MH, Leissner P, Verjat T, Ferlenghi I, Bagnoli F et al. Human endogenous retrovirus K (HML-2) elements in the plasma of people with lymphoma and breast cancer. J Virol 2008; 82: 9329-9336.
16. Wang-Johanning F, Rycaj K, Plummer JB, Li M, Yin B, Frerich K et al. Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope protein antibodies in targeting breast tumors. J Natl Cancer Inst 2012; 104: 189-210.
17. Armbruester V, Sauter M, Krautkraemer E, Meese E, Kleiman A, Best B et al. A novel gene from the human endogenous retrovirus K expressed in transformed cells. Clin Cancer Res 2002; 8: 1800-1807.
18. Büscher K, Trefzer U, Hofmann M, Sterry W, Kurth R, Denner J. Expression of human endogenous retrovirus K in melanomas and melanoma cell lines. Cancer Res 2005; 65: 4172-4180.
19. Xu R, Gao Q, Wang S, Kan H, Sheng L, Li C et al. Human acute myeloid leukemias may be etiologically associated with new human retroviral infection. Leuk Res 1996; 20: 449-455.
20. Oteiza A, Mechti N. The human T-cell leukemia virus type 1 oncoprotein tax controls forkhead box O4 activity through degradation by the proteasome. J Virol 2011; 85: 6480-6491.
21. Boese A, Sauter M, Galli U, Best B, Herbst H, Mayer J et al. Human endogenous retrovirus protein cORF supports cell transformation and associates with the promyelocytic leukemia zinc finger protein. Oncogene 2000; 19: 4328-4336.
22. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007; 318: 287-290.
23. Gandillet A, Park S, Lassailly F, Griessinger E, Vargaftig J, Filby A et al. Heterogeneous sensitivity of human acute myeloid leukemia to b-catenin downmodulation. Leukemia 2011; 25: 770-780.
24. Yeung J, Esposito MT, Gandillet A, Zeisig BB, Griessinger E, Bonnet D et al. b-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 2010; 18: 606-618.
25. Tatarek J, Cullion K, Ashworth T, Gerstein R, Aster JC, Kelliher MA. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL. Blood 2011; 118: 1579-1590.
26. Ito T, Kwon HY, Zimdahl B, Congdon KL, Blum J, Lento WE et al. Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature 2010; 466: 765-768.
27. Wang J, Liu Y, Li Z, Du J, Ryu MJ, Taylor PR et al. Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia. Blood 2010; 116: 5991-6002.
28. Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf CR, Bäsecke J et al. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia 2011; 25: 1080-1094.
29. Gutierrez A, Grebliunaite R, Feng H, Kozakewich E, Zhu S, Guo F et al. Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. J Exp Med 2011; 208: 1595-1603.
30. Polak R, Buitenhuis M. The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia. Blood 2011; 199: 911-923.
31. Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B et al. AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell 2011; 146: 697-708.
32. Hu Y, Chen Y, Douglas L, Li S. Beta-catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia 2009; 23: 109-116.
33. Armbruester V, Sauter M, Roemer K, Best B, Hahn S, Nty A et al. Np9 protein of human endogenous retrovirus K interacts with ligand of numb protein X. J Virol 2004; 78: 10310-10319.
34. Nie J, McGill MA, Dermer M, Dho SE, Wolting CD, McGlade CJ. LNX functions as a RING type E3 ubiquitin ligase that targets the cell fate determinant Numb for ubiquitin-dependent degradation. EMBO J 2002; 21: 93-102.
35. Denne M, Sauter M, Armbruester V, Licht JD, Roemer K, Mueller-Lantzsch N. Physical and functional interactions of human endogenous retrovirus proteins Np9 and rec with the promyelocytic leukemia zinc finger protein. J Virol 2007; 81: 5607-5616. Innovative Health Talents